Covid-19 YMC Informationen
- Applikationen für Substanzen in der Covid-19-Forschung
- Applikationem für RNA-Analysen, die für die Impfstoffherstellung nützlich sind
- Auswahl an Publikationen zu Covid-19-verwandten Verbindungen
- YMC-Säulenempfehlungen für die verwendeten Methoden
| Anwendung | Säule | Verbindung | |
| Adrenocorticosteroids | J'sphere ODS-H80 | Hydrocortisone Cortisone Methylprednisolone Betamethasone Dexamethasone Corticosterone Beclomethasone Triamcinolone acetonide | |
| Chloroquine | CHIRAL ART Amylose-SA | Chloroquine | |
| HPLC Analysis of Oligonucleotides Using YMC’s Non-porous AEX Columns | BioPro IEX QF | Synthetic oligonucleotides (Single-strand RNA, Single-strand DNA) | |
| Hydroxychloroquine Sulfate Tablets (USP 37th) | YMC-Triart C18 | Hydroxychloroquine sulfate Chloroquine phosphate | |
| LC/MS analysis of oligonucleotides (siRNA) | YMC-Triart C18 | 5'-GU ACG CGG AAU ACU UCG AdTdT-3' (20 nt) 5'-CGU ACG CGG AAU ACU UCG AdTdT-3' (21 nt) | |
| LC/MS analysis of oligonucleotides (miRNA) | YMC-Triart C18 | 5'-pUGG AGU GUG ACA AUG GUG UUG-3' (21 nt) 5'-pUGG AGU GUG ACA AUG GUG UUG U-3' (22 nt) | |
| Optimisation of oligonucleotide separations using YMC´s non porous anion exchanger BioPro IEX QF | BioPro IEX QF | Single strand DNA Single Strand RNA Single Strand 2'-OMe RNA | |
| Optimisation of phosphorothioate oligonucleotide separation using BioPro IEX QF | BioPro IEX QF | Phosphorothioated Single Strand RNA | |
| Synthetic oligonucleotides (Single-strand RNA) | BioPro IEX QF | 5’-U(M)C(M)A(M)U(M)C(M)A(M)C(M)A(M)C(M) U(M)G(M)A(M)A(M)U(M)A(M)C(M)C(M)A(M)A(M)U(M)-3’ (20 mer) 5’-G(M)U(M)C(M)A(M)U(M)C(M)A(M)C(M)A(M)C(M)U(M) G(M)A(M)A(M)U(M)A(M)C(M)C(M)A(M)A(M)U(M)-3’ (21 mer) | |
| UHPLC separation of hydroxychloroquine and chloroquine | YMC-Triart C18 | Hydroxychloroquine sulfate Chloroquine phosphate |
| Substance(s) evaluated | Publication Titel | Used/Recommended YMC Column | Reference |
| Fluoxetine | Simultaneous Determination of Olanzapine and Fluoxetine by HPLC | (5 µm) 150 x 4.6 mm ID (TA12S05-1546PTH) | B. V. Reddy et al., Chromatographia 66 (2007) 111-114. |
| Dexamethasone | Development and validation of HPLC method for analysis of dexamethasone acetate in microemulsions | (5 µm) 250 x 4.6 mm ID (TA12S05-2546PTH) | M. C. Cocenza Urban et al., Brazilian Journal of Pharmaceutical Sciences vol. 45, 1 (2009) 87-92. |
Dexamethasone | Dexamethasone Monograph | (5 µm) 150 x 4.6 mm ID (TA12S05-1546PTH) | Ph. Eur. 7 (2010) |
Ritonavir | United States Patent: Ritonavir Bis-Hydrochloride | (3 µm) 150 x 4.6 mm ID (BU12S03-1546WT) | M. Acquasaliente et al. United States Patent, Patent No. US 8.598.216 B1 (2013). |
Ritonavir | Development and Validation of a Simple, Sensitive, Selective and Stability-Indicating RP-UPLC Method for the Quantitative Determination of Ritonavir and Its Related Compounds | (1.9 µm) 100 x 2.1 mm ID (TA12SP9-10Q1PT) | S. Koppala et al., Journal of Chromatographic Science, 53 (2015) 662–675. |
Ritonavir | Ritonavir Monograph | YMC-Pack Pro C4 (3 µm) 150 x 4.6 mm ID (BS12S03-1546WT) | Ph. Eur. 8 (2014) |
Lopinavir | Lopinavir Monograph | (3 µm) 250 x 4.6 mm ID (TA12S03-2546PTH) | Ph. Eur. 8 (2014) |
Ritonavir, Lopinavir | RP-HPLC method for simultaneous estimation of antiretroviral drugs lopinavir and ritonavir in table dosage form | YMC-Triart C18 (5 µm) 250 x 4.6 mm ID (TA12S05-2546PTH) | I. Ponnilavarasan et al., Digest Journal of Nanomaterials and Biostructures Vol. 5, 3 (2010) 771-778. |
Fenofibrate | Phase separation of supersaturated solution created from amorphous solid dispersions: Relevance to oral absorption | J’sphere ODS-H80 (4 µm) 75 x 4.6 mm ID (JH08S04-L546WT) | K. Kawakamia et al., European Journal of Pharmaceutics and Biopharmaceutics, 132 (2018) 146–156. |
Interferon alpha-2 | Study of aggregation, denaturation and reduction of interferon alpha-2 products by size-exclusion high-performance liquid chromatography with fluorescence detection and biological assays | YMC-SEC MAB (3 µm) 300 x 8.0 mm ID (DLM25S03-3008WT) + YMC-Pack Diol-120 (5 µm) 300 x 8.0 mm ID (DL12S05-3008WT) | A. Diress et al., Journal of Chromatography A, 1217 (2010) 3297–3306. |
Chloroquine | Identification of Falsified Chloroquine Tablets in Africa at the Time of the COVID-19 Pandemic | YMC-Triart C18 (5 µm) 250 x 4.0 mm ID (TA12S05-2504PTH) + YMC-Triart C18 (5 µm) 150 x 4.6 mm ID (TA12S05-1546PTH) | G. Gnegel et al., American Journal of Tropical Medicine and Hygiene, 00 (2020) 1–4. |
Chloroquine | In vitro Metabolic Stability Study of New Cyclen Based Antimalarial Drug Leads Using RP-HPLC and LC-MS/MS | YMC-Triart C18 (5 µm) 150 x 4.6 mm ID (TA12S05-1546PTH) + YMC-Triart C18 (5 µm) 250 x 4.6 mm ID (TA12S05-2546PTH) | A. V. Rudraraju et al., Modern Chemistry & Applications, 2 (2014) 129. |
Fingolimod | Absorption and Disposition of the Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) in Healthy Volunteers: A Case of Xenobiotic Biotransformation Following Endogenous Metabolic Pathways | YMC-Triart C8 (3 µm) 50 x 4.6 mm ID TO12S03-0546PTH) | M. Zollinger et al., Drug Metabolism and Disposition, 39:2 (2011) 199-207. |
Pirfenidone | Development and Substantiation of a RP-HPLC Method for Monitoring of Impurities in Pirfenidone Drug Substance | YMC-Triart C18 (5 µm) 250 x 4.6 mm ID (TA12S05-2546PTH) | S. B. Bodempudi et al., American Journal of Analytical Chemistry, 6 (2015) 1019-1029. |
Favipiravir | Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever | (5 µm) 250 x 4.6 mm ID (AA12S05-2546WT) | B. B. Gowen et al., Antiviral Research, 121 (2015) 132–137. |
Penciclovir | Simultaneous determination of aciclovir, ganciclovir, and penciclovir in human plasma by high-performance liquid chromatography with fluorescence detection | (5 µm) 250 x 4.6 mm ID (TA12S05-2546PTH) | Y. Dao et al., Journal of Chromatography B, 867 (2008) 270–276. |
Ribavirin | HPLC–MS/MS method for the intracellular determination of ribavirin monophosphate and ribavirin triphosphate in CEMss cells | (3 µm) 100 x 1.0 mm ID (AS12S03-1001WT) | M. Meléndez et al., Journal of Pharmaceutical and Biomedical Analysis, 49(5) (2012) 1233–1240. |
Nafamostat mesylate | Identification of impurities in nafamostat mesylate using HPLC-IT-TOF/MS: A series of double-charged ions | (3 µm) 100 x 4.6 mm ID (2x TA12S03-1046PTH) | Y. Zhang et al., Journal of Pharmaceutical Analysis (2020). |
